Nadia Rubis

Bergamo, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Thyroid Hormones Exhibit Promising Prognostic and Therapeutic Potential in Autosomal Dominant Polycystic Kidney Disease.

Thyroid Hormones Exhibit Promising Prognostic and Therapeutic Potential in Autosomal Dominant Polycystic Kidney Disease.

Journal: Thyroid : official journal of the American Thyroid Association
Published: June 15, 2026

Randomized Controlled Clinical Trial of Allogeneic Mesenchymal Stromal Cell Infusion in Diabetic Kidney Disease.

Randomized Controlled Clinical Trial of Allogeneic Mesenchymal Stromal Cell Infusion in Diabetic Kidney Disease.

Journal: Kidney international reports
Published: December 17, 2025

Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy.

Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy.

Journal: Kidney international reports
Published: October 14, 2025

Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy.

Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy.

Journal: Kidney international reports
Published: September 26, 2025

Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD.

Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD.

Journal: Kidney international reports
Published: February 05, 2025

A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by Neanderthals.

A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by Neanderthals.

Journal: iScience
Published: May 16, 2023

Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.

Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: April 18, 2023

Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).

Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).

Journal: Journal of the American Society of Nephrology : JASN
Published: March 22, 2023

A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome.

A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome.

Journal: JCI insight
Published: March 08, 2023

Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.

Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.

Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: July 29, 2022

Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial).

Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial).

Journal: Diabetes research and clinical practice
Published: October 12, 2021

A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2).

A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2).

Journal: Frontiers in medicine
Published: September 29, 2021
Showing 1-12 of 25

Last Updated: 09/26/2026